Clin2
NCT07116915Possibly a fitRecruiting

Testing a new COPD inhaler for safety and effectiveness

COPD

Part of Lungs & breathing clinical trials.

This trial tests a new inhaled medication, HRS-9821, in healthy people and in people with COPD. For COPD patients, the goal is to see how safe and well-tolerated multiple doses are, which could lead to a new treatment option.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
160 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must be between 40 and 75 years old if you have COPD
  • You must have a confirmed diagnosis of COPD
  • Your lung function tests must show moderate to severe COPD (FEV1 between 40% and 80% of normal)
  • You must have smoked at least 10 pack-years (for example, 1 pack a day for 10 years)
  • You must be willing to stop your current COPD medications temporarily during the trial
  • You must have a normal chest X-ray at the start of the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07567872Recruiting· Phase 1
Inhaled HRS-9821 Safety Study in Healthy People and COPD Patients

This is an early-stage study testing a new inhaled medication (HRS-9821) to see if it is safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with COPD (chronic lung disease) to understand if it might help with breathing.

Chengdu, Sichuan
NCT07640451Recruiting· Phase 2
HRS-9821 inhalation treatment for moderate to severe COPD

This trial tests whether an inhaled medication called HRS-9821 can help people with moderate to severe COPD (chronic obstructive pulmonary disease) breathe better and reduce symptoms. You inhale the medication, and researchers will measure how well your lungs work and how you feel over time.

Shanghai, Shanghai Municipality
NCT07285122Recruiting· Phase 1
Inhaled study drug for healthy smokers and people with COPD

This study tests an inhaled medication called RB042 in healthy adults, healthy smokers, and people with COPD. It aims to see how the drug works in the body and whether it is safe, which could help in developing a new treatment for COPD.

Nedlands, Western Australia
NCT07140328Recruiting· Phase 2
Testing a new inhaler for COPD symptoms

This trial tests two forms of a new medication (HSK39004) in people with COPD. The goal is to see if they help improve breathing and are safe. Eligible participants must be between 40 and 80, have moderate to severe COPD, and be able to stop other COPD treatments during the study.

Nanchang, Jiangsu
NCT07658339Not yet recruiting· Phase 3
Testing an inhaled drug for COPD symptoms

This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.

Beijing
NCT07583849Recruiting· Phase 3
Testing a new inhaled powder for COPD symptoms

This study tests whether a new inhaled medication called HSK39004 can help people with COPD breathe better and reduce shortness of breath. You'll receive either the medication or a placebo (inactive powder) and be monitored for safety and effectiveness.

Beijing, Beijing Municipality

Hear when a new COPD trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.